Sutro Biopharma, Inc.
STRO- 1M
- -42.0%
Sutro Biopharma, Inc. in brief
Sutro Biopharma, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. Its market value was $155 M on 26 October 2026, which makes it the 17,182nd largest listed company in the world and the 3,296th largest in the USA on this site. In the year to December 2025 it had sales of $102 M and a net loss of $191 M. It employs about 224 people and Jane Chung is its chief executive. Its shares trade under the symbol STRO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Sutro Biopharma, Inc.
Healthcare sector company which develops therapies related to Cancer. Headquarters is in California, USA.
Sutro Biopharma, Inc. timeline
- 2006
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2007
- ✎Renamed Sutro Biopharma IncFormerly Fundamental Applied Biology Inc.
- 2018
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 27 September 2018; shares registered for exchange trading on 18 September 2018.
- 2023
- 💰Record revenue of $154 millionFY2023, the highest of the 8 years on record.
Events of Sutro Biopharma, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,035 (Jan 2020) · #2,227 (Jan 2021) · #3,306 (Jan 2022) · #2,866 (Dec 2022) · #3,339 (Jul 2023) · #3,017 (Jan 2024) · #1,333 (Mar 2026) · #2,777 (Aug 2026) · #2,961 (Sep 2026) · #3,300 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 1.5×
- Price / book
- —
- Free cash flow yield
- 7.2%
- Net margin
- -186.5%
- Operating margin
- -154.5%
- Return on equity
- —
- Liabilities / assets
- 176.2%
- Net debt
- $-65M
- Revenue growth
- +65.2%
- R&D / revenue
- 162.4%
- Revenue per employee
- $458 K
- Profit per employee
- $-853 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $102M | +65.2% | $-158M | $-191M | -186.5% |
| Dec 2024 | $62M | -59.6% | $-238M | $-227M | -366.6% |
| Dec 2023 | $154M | +126.8% | $-89M | $-107M | -69.5% |
| Dec 2022 | $68M | +9.5% | $-129M | $-119M | -175.9% |
| Dec 2021 | $62M | +44.9% | $-99M | $-106M | -170.6% |
| Dec 2020 | $43M | -0.0% | $-71M | $-32M | -75.2% |
| Dec 2019 | $43M | +11.2% | $-55M | $-119M | -278.9% |
| Dec 2018 | $38M | — | $-37M | $-35M | -91.9% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-177M | — | — | $-22.49 | — |
| Dec 2024 | $-192M | — | — | $-29.40 | — |
| Dec 2023 | $-112M | — | — | $-1.78 | — |
| Dec 2022 | $4M | — | — | $-2.35 | — |
| Dec 2021 | $-82M | — | — | $-2.29 | — |
| Dec 2020 | $-68M | — | — | $-0.99 | — |
| Dec 2019 | $-65M | — | — | $-2.43 | — |
| Dec 2018 | $13M | $2M | $11M | $-6.13 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $9M (-6.1% on a year earlier), net income $-31M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jun 8, 20268-KCurrent reportShareholder vote
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportResults of operations
- Apr 22, 2026DEF 14AProxy statement
- Mar 23, 202610-KAnnual report · period to Dec 2025
- Mar 23, 20268-KCurrent reportAgreement ended · Results of operations
- Feb 10, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Dec 17, 20258-KCurrent reportOther events
Official filings of Sutro Biopharma, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $102 M
- Operating income
- $-158 M
- Net income
- $-191 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $174 M
- Total liabilities
- $306 M
- Total equity
- $-132 M
As of December-2025
Top 100 institutional investors in Sutro Biopharma, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BVF Inc/il | 1,251,788 | 0 (0.00%) | 7.54% | $20 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 1,178,196 | +55,541 (+4.95%) | 7.10% | $19 M | Nov 13, 2026 |
| 3 | Affinity Asset Advisors, LLC | 1,152,487 | -20,000 (-1.71%) | 6.94% | $19 M | Nov 13, 2026 |
| 4 | Samsara Biocapital, LLC | 1,062,872 | 0 (0.00%) | 6.40% | $17 M | Nov 16, 2026 |
| 5 | Perceptive Advisors LLC | 970,846 | -334,000 (-25.60%) | 5.85% | $16 M | Nov 16, 2026 |
| 6 | Kynam Capital Management, LP | 872,558 | 0 (0.00%) | 5.26% | $14 M | Nov 16, 2026 |
| 7 | Orbimed Advisors LLC | 743,944 | 0 (0.00%) | 4.48% | $12 M | Nov 16, 2026 |
| 8 | Vanguard Capital Management LLC | 676,926 | -17,293 (-2.49%) | 4.08% | $11 M | Nov 13, 2026 |
| 9 | Acadian Asset Management LLC | 557,868 | +184,029 (+49.23%) | 3.36% | $9 M | Nov 9, 2026 |
| 10 | Velan Capital Investment Management LP | 510,038 | -2,122 (-0.41%) | 3.07% | $8 M | Nov 16, 2026 |
| 11 | Goldman Sachs Group Inc | 496,794 | +347,578 (+232.94%) | 2.99% | $8 M | Nov 16, 2026 |
| 12 | T. Rowe Price Investment Management, Inc. | 411,655 | New | 2.48% | $7 M | Nov 16, 2026 |
| 13 | Qube Research & Technologies Ltd | 379,290 | +272,680 (+255.77%) | 2.28% | $6 M | Nov 13, 2026 |
| 14 | Geode Capital Management, LLC | 365,851 | -23,841 (-6.12%) | 2.20% | $6 M | Nov 6, 2026 |
| 15 | Two Sigma Investments, LP | 358,075 | +156,387 (+77.54%) | 2.16% | $6 M | Nov 16, 2026 |
| 16 | Woodline Partners LP | 350,136 | -107,893 (-23.56%) | 2.11% | $6 M | Nov 16, 2026 |
| 17 | Ameriprise Financial Inc | 347,947 | +103,278 (+42.21%) | 2.10% | $6 M | Nov 16, 2026 |
| 18 | State Street Corp | 324,477 | +18,498 (+6.05%) | 1.95% | $5 M | Nov 12, 2026 |
| 19 | Marshall Wace, LLP | 317,964 | +142,718 (+81.44%) | 1.92% | $5 M | Nov 13, 2026 |
| 20 | Citadel Advisors LLC | 289,939 | +187,974 (+184.35%) | 1.75% | $5 M | Nov 16, 2026 |
| 21 | Vanguard Portfolio Management LLC | 282,764 | +85,202 (+43.13%) | 1.70% | $5 M | Nov 13, 2026 |
| 22 | Merck & Co., Inc. | 272,351 | 0 (0.00%) | 1.64% | $4 M | Nov 13, 2026 |
| 23 | ADAR1 Capital Management, LLC | 267,067 | -136,947 (-33.90%) | 1.61% | $4 M | Nov 16, 2026 |
| 24 | Elmind Capital, LP | 228,265 | +196,228 (+612.50%) | 1.38% | $4 M | Nov 16, 2026 |
| 25 | KVP Capital Advisors, LP | 226,575 | 0 (0.00%) | 1.36% | $4 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Jpmorgan Chase & Co | 225,840 | +66,213 (+41.48%) | 1.36% | $4 M | Nov 12, 2026 |
| 27 | Balyasny Asset Management L.P. | 223,114 | -488,048 (-68.63%) | 1.34% | $4 M | Nov 16, 2026 |
| 28 | Ra Capital Management, L.P. | 210,934 | New | 1.27% | $3 M | Nov 16, 2026 |
| 29 | FMR LLC | 171,245 | +169,906 (+12689.02%) | 1.03% | $3 M | Nov 10, 2026 |
| 30 | Point72 Asset Management, L.P. | 136,793 | -101,034 (-42.48%) | 0.82% | $2 M | Nov 16, 2026 |
| 31 | UBS Group AG | 115,058 | -93,454 (-44.82%) | 0.69% | $2 M | Nov 10, 2026 |
| 32 | Northern Trust Corp | 114,731 | -11,202 (-8.90%) | 0.69% | $2 M | Nov 16, 2026 |
| 33 | Vanguard Fiduciary Trust Co | 100,036 | -4,196 (-4.03%) | 0.60% | $2 M | Nov 13, 2026 |
| 34 | Seven Fleet Capital Management LP | 99,894 | -59,224 (-37.22%) | 0.60% | $2 M | Nov 16, 2026 |
| 35 | Y-Intercept (Hong Kong) Ltd | 90,536 | +34,657 (+62.02%) | 0.55% | $1 M | Oct 16, 2026 |
| 36 | Jacobs Levy Equity Management, Inc | 90,381 | New | 0.54% | $1 M | Nov 16, 2026 |
| 37 | Renaissance Technologies LLC | 87,247 | +923 (+1.07%) | 0.53% | $1 M | Nov 12, 2026 |
| 38 | Charles Schwab Investment Management Inc | 73,732 | +24,430 (+49.55%) | 0.44% | $1 M | Nov 16, 2026 |
| 39 | Mackenzie Financial Corp | 68,513 | -26,254 (-27.70%) | 0.41% | $1 M | Nov 2, 2026 |
| 40 | Invesco Ltd. | 64,885 | +7,580 (+13.23%) | 0.39% | $1 M | Nov 12, 2026 |
| 41 | BNP Paribas Financial Markets | 62,306 | +34,923 (+127.54%) | 0.38% | $1 M | Nov 12, 2026 |
| 42 | Wellington Management Group LLP | 58,319 | +47,519 (+439.99%) | 0.35% | $1 M | Nov 16, 2026 |
| 43 | Morgan Stanley | 55,238 | +42,882 (+347.05%) | 0.33% | $1 M | Nov 13, 2026 |
| 44 | Barclays PLC | 51,098 | +14,144 (+38.27%) | 0.31% | $1 M | Nov 6, 2026 |
| 45 | Bank of New York Mellon Corp | 41,369 | 0 (0.00%) | 0.25% | $1 M | Nov 5, 2026 |
| 46 | Fisher Asset Management, LLC | 35,295 | 0 (0.00%) | 0.21% | $1 M | Nov 6, 2026 |
| 47 | Nuveen, LLC | 34,872 | -133,125 (-79.24%) | 0.21% | $1 M | Nov 10, 2026 |
| 48 | XTX Topco Ltd | 33,271 | -18,898 (-36.22%) | 0.20% | $1 M | Nov 16, 2026 |
| 49 | HSBC Holdings PLC | 29,853 | +23,619 (+378.87%) | 0.18% | $0 M | Nov 16, 2026 |
| 50 | Susquehanna Portfolio Strategies, LLC | 28,242 | New | 0.17% | $0 M | Nov 16, 2026 |
| 51 | Squarepoint Ops LLC | 28,193 | -27,346 (-49.24%) | 0.17% | $0 M | Nov 9, 2026 |
| 52 | Los Angeles Capital Management LLC | 26,706 | New | 0.16% | $0 M | Nov 12, 2026 |
| 53 | Massachusetts Financial Services Co /ma/ | 25,850 | New | 0.16% | $0 M | Nov 12, 2026 |
| 54 | Verdad Advisers, LP | 25,499 | +19,099 (+298.42%) | 0.15% | $0 M | Nov 16, 2026 |
| 55 | Acuta Capital Partners, LLC | 25,290 | -244,961 (-90.64%) | 0.15% | $0 M | Nov 16, 2026 |
| 56 | Millennium Management LLC | 24,754 | -341,218 (-93.24%) | 0.15% | $0 M | Nov 16, 2026 |
| 57 | Man Group plc | 24,098 | New | 0.15% | $0 M | Nov 16, 2026 |
| 58 | Franklin Templeton Inc | 21,774 | New | 0.13% | $0 M | Nov 12, 2026 |
| 59 | Rhumbline Advisers | 21,525 | +897 (+4.35%) | 0.13% | $0 M | Nov 10, 2026 |
| 60 | Engineers Gate Manager LP | 19,228 | New | 0.12% | $0 M | Nov 16, 2026 |
| 61 | Public Employees Retirement System Of Ohio | 18,277 | New | 0.11% | $0 M | Nov 16, 2026 |
| 62 | Bank Of America Corp /de/ | 17,578 | -18,562 (-51.36%) | 0.11% | $0 M | Nov 16, 2026 |
| 63 | Connor, Clark & Lunn Investment Management Ltd. | 17,051 | New | 0.10% | $0 M | Nov 10, 2026 |
| 64 | Quadrature Capital Ltd | 16,866 | New | 0.10% | $0 M | Nov 13, 2026 |
| 65 | RBF Capital, LLC | 15,272 | 0 (0.00%) | 0.09% | $0 M | Nov 13, 2026 |
| 66 | TD Asset Management Inc | 14,554 | New | 0.09% | $0 M | Nov 13, 2026 |
| 67 | Deutsche Bank AG\ | 13,603 | -1,960 (-12.59%) | 0.08% | $0 M | Nov 6, 2026 |
| 68 | Price T Rowe Associates Inc /MD/ | 13,597 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 69 | Susquehanna Fundamental Investments, LLC | 13,508 | New | 0.08% | $0 M | Nov 16, 2026 |
| 70 | Jump Financial, LLC | 12,900 | New | 0.08% | $0 M | Nov 13, 2026 |
| 71 | Achmea Investment Management B.V. | 12,198 | New | 0.07% | $0 M | Oct 30, 2026 |
| 72 | Jain Global LLC | 11,675 | New | 0.07% | $0 M | Nov 16, 2026 |
| 73 | SEI Investments Co | 10,962 | -5,425 (-33.11%) | 0.07% | $0 M | Nov 10, 2026 |
| 74 | Persistent Asset Partners Ltd | 9,409 | +2,840 (+43.23%) | 0.06% | $0 M | Nov 13, 2026 |
| 75 | MetLife Investment Management, LLC | 9,401 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 76 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 6,881 | -432 (-5.91%) | 0.04% | $0 M | Nov 16, 2026 |
| 77 | New York State Common Retirement Fund | 5,600 | 0 (0.00%) | 0.03% | $0 M | Nov 17, 2026 |
| 78 | Vanguard Global Advisers, LLC | 5,508 | +63 (+1.16%) | 0.03% | $0 M | Nov 13, 2026 |
| 79 | Police & Firemen's Retirement System of New Jersey | 4,704 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 80 | Employees Retirement System of Texas | 4,679 | New | 0.03% | $0 M | Nov 10, 2026 |
| 81 | Tower Research Capital LLC (TRC) | 3,861 | +2,995 (+345.84%) | 0.02% | $0 M | Nov 16, 2026 |
| 82 | Legal & General Group Plc | 3,206 | -256 (-7.39%) | 0.02% | $0 M | Nov 16, 2026 |
| 83 | Wells Fargo & Company/mn | 3,039 | -10,505 (-77.56%) | 0.02% | $0 M | Nov 16, 2026 |
| 84 | State of Wyoming | 2,082 | +464 (+28.68%) | 0.01% | $0 M | Oct 28, 2026 |
| 85 | Ameritas Investment Partners, Inc. | 1,448 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 86 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,442 | New | 0.01% | $0 M | Nov 16, 2026 |
| 87 | Russell Investments Group, Ltd. | 1,442 | +167 (+13.10%) | 0.01% | $0 M | Nov 6, 2026 |
| 88 | Citigroup Inc | 1,189 | -6,267 (-84.05%) | 0.01% | $0 M | Nov 4, 2026 |
| 89 | FNY Investment Advisers, LLC | 1,000 | 0 (0.00%) | 0.01% | $0 M | Oct 16, 2026 |
| 90 | Royal Bank Of Canada | 759 | +72 (+10.48%) | 0.00% | $0 M | Nov 16, 2026 |
| 91 | Owl Creek Wealth Partners LLC | 491 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 92 | Sterling Capital Management LLC | 317 | +36 (+12.81%) | 0.00% | $0 M | Oct 22, 2026 |
| 93 | California State Teachers Retirement System | 220 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 94 | Physician Wealth Advisors, Inc. | 182 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 95 | GAMMA Investing LLC | 140 | New | 0.00% | $0 M | Oct 8, 2026 |
| 96 | Osaic Holdings, Inc. | 100 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 97 | Arax Advisory Partners | 67 | +51 (+318.75%) | 0.00% | $0 M | Nov 12, 2026 |
| 98 | Nisa Investment Advisors, LLC | 44 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 99 | HighMark Wealth Management LLC | 23 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 100 | Allworth Financial LP | 8 | New | 0.00% | $0 M | Nov 17, 2026 |
Mutual funds holding Sutro Biopharma, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC | 585,262 | $19 M | 3.5% | 1.1% | −18% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 501,524 | $17 M | 3.0% | <0.01% | −5.9% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 326,271 | $11 M | 2.0% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 177,208 | $6 M | 1.1% | <0.01% | +4.8% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 173,722 | $4 M | 1.0% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 98,529 | $3 M | 0.59% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Quant Small Cap Equity FundTeachers Advisors, LLC | 126,290 | $3 M | 0.76% | 0.08% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 78,053 | $2 M | 0.47% | <0.01% | +78% | May 31, 2026 |
| 🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc. | 60,304 | $2 M | 0.36% | 0.18% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 77,195 | $2 M | 0.46% | 0.18% | new | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P. | 66,530 | $2 M | 0.40% | 0.12% | new | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 47,714 | $2 M | 0.29% | 0.10% | +130% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 38,737 | $1 M | 0.23% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 27,815 | $1 M | 0.17% | <0.01% | +107% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 23,951 | $1 M | 0.14% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 28,467 | $1 M | 0.17% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Equity FundCharles Schwab Investment Management, Inc. | 28,234 | $1 M | 0.17% | 0.10% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 23,004 | $1 M | 0.14% | <0.01% | +107% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 18,817 | $1 M | 0.11% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 18,719 | $1 M | 0.11% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 21,156 | $1 M | 0.13% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 14,128 | $0 M | 0.09% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 13,899 | $0 M | 0.08% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation | 13,437 | $0 M | 0.08% | 0.18% | new | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 16,529 | $0 M | 0.10% | 0.01% | −3.7% | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 11,500 | $0 M | 0.07% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS | 10,345 | $0 M | 0.06% | 0.16% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 13,975 | $0 M | 0.08% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P. | 13,476 | $0 M | 0.08% | 0.10% | new | Jul 31, 2026 |
| 🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC | 8,860 | $0 M | 0.05% | 0.09% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 8,468 | $0 M | 0.05% | <0.01% | −9.3% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 8,229 | $0 M | 0.05% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 10,500 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 7,075 | $0 M | 0.04% | <0.01% | −20% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 6,882 | $0 M | 0.04% | 0.10% | new | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 5,900 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 7,595 | $0 M | 0.05% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 5,330 | $0 M | 0.03% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 4,773 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 4,574 | $0 M | 0.03% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 5,177 | $0 M | 0.03% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 4,102 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 3,561 | $0 M | 0.02% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 3,289 | $0 M | 0.02% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 3,173 | $0 M | 0.02% | 0.05% | +114% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 3,000 | $0 M | 0.02% | 0.07% | no change | Jun 30, 2026 |
| 🇺🇸 SA Multi-Managed Small Cap PortfolioSunAmerica Asset Management, LLC | 2,842 | $0 M | 0.02% | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 2,690 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 2,690 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 2,503 | $0 M | 0.02% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 2,406 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 2,347 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 2,341 | $0 M | 0.01% | <0.01% | −43% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 2,781 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 1,960 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC | 1,925 | $0 M | 0.01% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 1,734 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 1,701 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 1,448 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 1,868 | $0 M | 0.01% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 1,275 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,648 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 1,566 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 1,104 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 1,070 | $0 M | <0.01% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,412 | $0 M | <0.01% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 884 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 712 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 933 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 500 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 445 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 403 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 505 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 299 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 270 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 252 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 179 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 151 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 189 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 92 | $0 M | <0.01% | <0.01% | +114% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 80 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Sutro Biopharma, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Hans-Peter GerberCHIEF SCIENTIFIC OFFICER | Option exercise | +3,750 | — | — | 13,712 | Form 4 |
| filed | Hans-Peter GerberCHIEF SCIENTIFIC OFFICER | Shares withheld for tax | -1,345 | $15.34 | $21 K | 12,367 | Form 4 |
| filed | Gregory K. ChowCFO | Option exercise | +2,500 | — | — | 4,725 | Form 4 |
| filed | Jane ChungChief Executive Officer, Director | Option exercise | +788 | — | — | 21,567 | Form 4 |
| filed | David PaulingChief Admin. Ofcr. & GC | Option exercise | +675 | — | — | 10,025 | Form 4 |
| filed | Jane ChungChief Executive Officer, Director | Shares withheld for tax | -282 | $21.31 | $6 K | 21,285 | Form 4 |
| filed | David PaulingChief Admin. Ofcr. & GC | Shares withheld for tax | -277 | $21.31 | $6 K | 9,748 | Form 4 |
| filed | Hans-Peter GerberCHIEF SCIENTIFIC OFFICER | Option exercise | +2,843 | — | — | 10,688 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Sutro Biopharma, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split
Trading halts
- 2025-12-03 00:50 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 93 shares at $9.33
- : 5,090 shares at $11.54
- : 6,050 shares at $10.94
- : 2,640 shares at $10.52
- : 8 shares at $16.10
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Sutro Biopharma, Inc. scorecard#
Passes 8 of the 19 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (1 of 4). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median1.5×Price to sales 1.5× against Biotechnology's median of 8.7×.
- ✓Free cash flow yield above 5%7.2%Free cash flow is 7.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 6
- ✓Revenue grew in the newest year65.2%Revenue up 65.2% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years14.8%14.8% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median14.8%14.8% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-22.49 vs -29.40Diluted EPS -22.49 in fiscal 2025 against -29.40 the year before (report's currency).
- ✗Net income higher than five years earlier-$191 M-$191 M in fiscal 2025 against -$32 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability1 of 4
- ✗Profitable in the newest year-$191 MNet income -$191 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-154.5%-154.5% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-154.5%-154.5% in fiscal 2025 against -190.3% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.0×Current ratio 2.01 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-9.47Z-score -9.47 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year9.8%Diluted shares up 9.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Sutro Biopharma, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -154.5% | -60.5% | |
| Net margin | -186.5% | -68.9% | |
| Revenue growth, 3 years a year | 14.8% | 12.9% | |
| Revenue growth | 65.2% | 15.8% |
2of 7on the Piotroski tests of financial strength
- Net loss of $191 million, the 9th loss-making year in a row.
- The share count rose 9.8% in the year.
- Shareholders' equity is negative: -$132 million.
Sutro Biopharma, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 102+65.2%100% | 62−59.6%100% | 154+127%100% | 68+9.5%100% | 62+44.8%100% | 43−0.0%100% | 43+11.2%100% | 38−25.7%100% | 52−13.4%100% | 60—100% | |
| Research and development | 166−34.0%162% | 252+39.7%406% | 180+31.5%117% | 137+31.4%202% | 104+35.7%169% | 77+17.3%180% | 66+20.9%154% | 54−0.7%141% | 55+25.5%106% | 44—72.9% | |
| General and administrative | 41−15.3%40.0% | 48−22.6%78.1% | 63+5.1%40.7% | 60+6.3%87.9% | 56+52.1%90.5% | 37+13.0%86.2% | 33+52.4%76.3% | 21+30.6%55.6% | 16+10.5%31.6% | 15—24.8% | |
| Operating expenses | 261−13.2%255% | 300+23.7%484% | 243+23.5%158% | 197+22.6%290% | 160+41.0%259% | 114+15.9%266% | 98+29.8%230% | 76+6.5%197% | 71+21.7%137% | 58—97.7% | |
| Operating income | −158—−155% | −238—−384% | −89—−58.1% | −129—−190% | −99—−159% | −71—−166% | −55—−130% | −37—−96.9% | −19−1513%−37.2% | 1.4—2.3% | |
| Interest expense and finance costs | — | — | 1.3−45.8%0.8% | 2.4−7.7%3.5% | 2.6+13.0%4.2% | 2.3+109%5.4% | 1.1−32.2%2.6% | 1.6+165%4.2% | 0.6—1.2% | 0—0.0% | |
| Net interest income | — | — | — | — | — | — | −4.4—−10.2% | — | — | — | |
| Other non-operating income (expense) | — | — | — | — | — | — | — | 1.9—5.0% | −0.1−189%−0.1% | 0.1—0.1% | |
| Income before tax | −191—−187% | −225—−363% | −89—−57.6% | −117—−172% | −106—−171% | −32—−75.0% | — | — | — | — | |
| Income tax | −0.1−104%−0.1% | 2.4−87.0%3.8% | 18+628%11.8% | 2.5—3.7% | 0−100%0.0% | 0.1r0.1—0.2% | 0—0.0% | 0—0.0% | 0—0.0% | — | |
| Net income including minority interests | −191—−186% | −227—−367% | −107—−69.5% | −119—−176% | −106—−171% | −32—−75.2% | −56—−130% | −35—−91.9% | −20−1257%−38.1% | 1.7—2.8% | |
| Net income attributable to shareholders | −191—−186% | −227—−367% | −107—−69.5% | −119—−176% | −106—−171% | −32—−75.2% | −56—−130% | −35—−91.9% | −20−1257%−38.1% | 1.7—2.8% | |
| Earnings per share, basic | -22.49—— | -29.40r-2.96—— | -1.78—— | -2.35—— | -2.29—— | -0.99—— | -2.43—— | -6.13—— | -43.95—— | 0.00—— | |
| Earnings per share, diluted | -22.49—— | -29.40r-2.96—— | -1.78—— | -2.35—— | -2.29—— | -0.99—— | -2.43—— | -6.13—— | -43.95—— | 0.00—— | |
| Shares, weighted average (basic) | 8.5+9.8%— | 7.7r77−87.1%— | 60+18.6%— | 51+10.0%— | 46+41.6%— | 33—— | — | — | — | — | |
| Shares, weighted average (diluted) | 8.5+9.8%— | 7.7r77−87.1%— | 60+18.6%— | 51+10.0%— | 46+41.6%— | 33+41.9%— | 23+299%— | 5.8+1186%— | 0.4+9.9%— | 0.4—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 58−69.5%33.4% | 190+175%49.1% | 69+46.6%14.7% | 47+55.4%11.6% | 30−85.2%8.9% | 206+4056%52.3% | 5.0−96.0%3.2% | 125+469%56.2% | 22+89.9%54.0% | 12—— | |
| Short-term investments | 83−34.2%47.9% | 127−52.1%32.7% | 264+3.7%56.2% | 255+95.7%62.7% | 130+8.3%38.2% | 120+6.6%30.5% | 113+42.6%72.2% | 79—35.5% | — | — | |
| Receivables | 4.0−53.8%2.3% | 8.6−76.1%2.2% | 36+407%7.7% | 7.1−42.8%1.8% | 12+124%3.6% | 5.6−11.7%1.4% | 6.3+153%4.0% | 2.5+53.3%1.1% | 1.6—4.0% | — | |
| Other current assets | 5.5−69.0%3.2% | 18+80.8%4.6% | 9.8−15.6%2.1% | 12+43.6%2.9% | 8.1+81.1%2.4% | 4.5+1.8%1.1% | 4.4+48.6%2.8% | 3.0+49.4%1.3% | 2.0—4.9% | — | |
| Current assets | 151−56.0%86.8% | 343−18.6%88.7% | 422+19.4%89.5% | 353+61.6%86.8% | 219−42.2%64.0% | 378+194%96.0% | 129−38.8%82.2% | 210+719%94.1% | 26—62.9% | — | |
| Property, plant and equipment | 11−41.5%6.1% | 18−17.1%4.7% | 22−10.9%4.7% | 25+9.2%6.1% | 23+74.3%6.6% | 13+34.3%3.3% | 9.6−11.9%6.2% | 11−21.9%4.9% | 14—34.3% | — | |
| Right-of-use (leased) assets | 11−38.3%6.3% | 18−22.5%4.6% | 23−13.7%4.8% | 26−8.9%6.5% | 29—8.5% | — | — | — | — | — | |
| Total assets | 174−55.1%100% | 387−17.7%100% | 471+15.7%100% | 407+19.2%100% | 341−13.4%100% | 394+152%100% | 156−29.9%100% | 223+447%100% | 41—100% | — | |
| Accounts payable | 7.6−27.8%4.4% | 10+11.0%2.7% | 9.4+96.8%2.0% | 4.8−20.2%1.2% | 6.0r11+8.4%1.8% | 5.5−0.7%1.4% | 5.6+82.4%3.6% | 3.1+5.5%1.4% | 2.9—7.1% | — | |
| Debt due within a year | — | — | 4.1−67.5%0.9% | 13+33.3%3.1% | 9.4—2.7% | — | 1.0−78.8%0.6% | 4.7−67.6%2.1% | 15r15—35.7% | — | |
| Current liabilities | 75−43.0%43.2% | 132+40.7%34.1% | 94+40.9%19.9% | 67+59.4%16.4% | 42+41.0%12.2% | 30−10.2%7.5% | 33−9.5%21.1% | 36+14.0%16.3% | 32—78.4% | — | |
| Long-term debt | — | — | 0−100%0.0% | 3.8−76.0%0.9% | 16−35.9%4.6% | 25+177%6.2% | 8.9−11.2%5.7% | 10—4.5% | — | — | |
| Lease liabilities (non-current) | 7.9−49.7%4.5% | 16−32.3%4.0% | 23−21.7%4.9% | 30−5.3%7.3% | 31—9.1% | — | — | — | — | — | |
| Total liabilities | 306−10.6%176% | 343+6.7%88.5% | 321+69.1%68.2% | 190+114%46.7% | 89+43.2%26.0% | 62+5.9%15.7% | 59−36.0%37.5% | 92+93.8%41.1% | 47—116% | — | |
| Retained earnings | −978—−563% | −787—−203% | −559—−119% | −453—−111% | −333—−97.7% | −228—−57.8% | −196—−125% | −150—−67.4% | −115—−282% | — | |
| Shareholders' equity | −132−397%−76.2% | 45−70.2%11.5% | 150−31.1%31.8% | 217−14.1%53.3% | 253−23.9%74.0% | 332+240%84.3% | 98−25.7%62.5% | 132—58.9% | −109—−267% | −91—— | |
| Total liabilities and equity | 174−55.1%100% | 387−17.7%100% | 471+15.7%100% | 407+19.2%100% | 341−13.4%100% | 394+152%100% | 156−29.9%100% | 223+447%100% | 41—100% | — | |
| Shares outstanding | 8.6+3.3%— | 8.3r83−86.4%— | 61+6.1%— | 57+24.1%— | 46+1.3%— | 46+98.1%— | 23+1.1%— | 23+4810%— | 0.5—— | — | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 7.3+1.5%7.1% | 7.2+5.9%11.6% | 6.8+19.8%4.4% | 5.7+17.5%8.4% | 4.8+12.7%7.8% | 4.3−10.0%10.1% | 4.8+5.2%11.2% | 4.5−9.0%11.8% | 5.0−11.9%9.6% | 5.7—9.5% | |
| Share-based compensation | 14−43.3%13.7% | 25−0.9%39.8% | 25−5.3%16.2% | 26+13.2%38.8% | 23+95.0%37.6% | 12+15.6%27.9% | 10+259%24.1% | 2.9+106%7.5% | 1.4+43.7%2.7% | 1.0—1.6% | |
| Cash from operating activities | −177—−173% | −192—−309% | −112−3245%−72.6% | 3.5—5.2% | −82—−132% | −68—−159% | −65−613%−152% | 13—33.0% | −37—−71.7% | −13—−22.0% | |
| Capital expenditure | — | — | — | — | — | — | — | −1.6—−4.1% | −3.3—−6.4% | −4.4—−7.4% | |
| Cash from investing activities | 45−79.4%43.9% | 219—352% | −3.9—−2.6% | −35—−51.7% | −97−16212%−157% | 0.6—1.4% | −51—−120% | −80−346%−209% | 33+240%63.0% | 9.6—16.1% | |
| Debt issued | — | — | — | — | — | 25—58.5% | — | 0−100%0.0% | 15—29.0% | 0—0.0% | |
| Debt repaid | 0—0.0% | −4.1—−6.6% | −13—−8.1% | −9.4—−13.8% | — | −10—−23.4% | −5.0—−11.7% | — | — | — | |
| Shares issued | 0−100%0.0% | 25—40.3% | 0r12—0.0% | 0r56—0.0% | — | 251—588% | −0.3—−0.8% | — | — | — | |
| Shares bought back | — | — | — | — | −0.0—−0.0% | — | — | — | — | — | |
| Cash from financing activities | 0.0−100.0%0.0% | 94−31.6%152% | 138+185%89.5% | 48+1384%71.3% | 3.3−98.8%5.3% | 269—630% | −4.2−102%−9.8% | 171+1067%445% | 15+8170%28.3% | 0.2—0.3% | |
| Change in cash | −132−209%−129% | 121+450%195% | 22+30.7%14.3% | 17—24.8% | −176−187%−284% | 202—473% | −120−217%−282% | 103+916%269% | 10—19.6% | −3.4—−5.7% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 45−57.3%100% | 9.1−6.1%100% | 9.8−84.6%100% | 15−16.5%100% | 12*−21.4%100% | 9.7+13.8%100% | 64+148%100% | 17+33.8%100% | 15*−87.0%100% | 8.5—100% | 26—100% | 13—100% | 114*—100% | |
| Research and development | 128−36.1%285% | 23−41.0%258% | 32−17.3%322% | 37−29.2%252% | 37*−48.4%315% | 40−35.8%411% | 38−38.2%60.1% | 52−9.3%297% | 71*+32.1%480% | 62—729% | 62—241% | 57—437% | 54*—47.3% | |
| General and administrative | 32−23.6%70.1% | 7.5−13.8%82.9% | 7.8−24.3%79.6% | 7.6−42.9%52.2% | 8.7*−4.1%74.4% | 8.7−39.0%90.2% | 10−16.4%16.2% | 13+4.3%76.3% | 9.0*−46.3%61.0% | 14—168% | 12—48.1% | 13—97.8% | 17*—14.8% | |
| Operating expenses | 165−43.5%365% | 31−46.6%341% | 40−40.8%404% | 44−48.6%304% | 50*−37.9%427% | 58−23.9%600% | 67−9.8%105% | 86+23.4%494% | 80*+13.5%541% | 76—897% | 74—289% | 70—535% | 71*—62.1% | |
| Operating income | −120—−265% | −22—−241% | −30—−304% | −30—−204% | −38*—−327% | −48—−500% | −3.3—−5.2% | −69—−394% | −65*−251%−441% | −68—−797% | −49—−189% | −57—−435% | 43*—37.9% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | — | — | — | 0.2*—0.2% | |
| Other non-operating income (expense) | — | −9.5—−105% | — | — | — | −8.4—−86.6% | — | — | — | — | — | — | — | |
| Income before tax | −155—−344% | −31—−346% | −39—−392% | −38—−265% | −47*—−402% | −57—−587% | −12—−18.1% | −76—−437% | −70*−250%−473% | −49—−573% | −48—−187% | −58—−448% | 47*—41.2% | |
| Income tax | −0.1−104%−0.2% | 0—0.0% | 0.0—0.0% | −0.0−314%−0.1% | −0.1*−103%−0.7% | 0—0.0% | −0.0−325%−0.0% | 0.0—0.0% | 2.4*−85.1%15.9% | 0—0.0% | 0.0—0.0% | — | 16*—13.9% | |
| Net income including minority interests | −155—−344% | −31*—−346% | −39*—−392% | −38—−265% | −47*—−401% | −57*—−587% | −11*—−18.0% | −76—−437% | −72*−333%−489% | −49*—−573% | −48*—−187% | −58—−448% | 31*—27.3% | |
| Net income attributable to shareholders | −155—−344% | −31—−346% | −39—−392% | −38—−265% | −47*—−401% | −57—−587% | −11—−18.0% | −76—−437% | −72*−333%−489% | −49—−573% | −48—−187% | −58—−448% | 31*—27.3% | |
| Earnings per share, basic | — | -1.90—— | -2.33—— | -2.94—— | — | -6.66r-0.67—— | -1.35r-0.14—— | -9.08r-0.91—— | — | -0.59—— | -0.59—— | -0.59r-0.95—— | — | |
| Earnings per share, diluted | — | -1.90—— | -2.33—— | -2.94—— | — | -6.66r-0.67—— | -1.35r-0.14—— | -9.08r-0.91—— | — | -0.59—— | -0.59—— | -0.59r-0.95—— | — | |
| Shares, weighted average (basic) | 17+94.2%— | 17+94.2%— | 17+94.7%— | 13+56.4%— | — | 8.5r85−89.6%— | 8.5r85−89.5%— | 8.4r83−86.4%— | — | 82—— | 81—— | 61—— | — | |
| Shares, weighted average (diluted) | 17+94.2%— | 17+94.2%— | 17+94.7%— | 13+56.4%— | — | 8.5r85−89.6%— | 8.5r85−89.5%— | 8.4r83−86.4%— | — | 82—— | 81—— | 61—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 47—26.5% | 47−28.9%26.5% | 54−15.1%27.9% | 74−30.6%30.4% | 58−69.5%33.4% | 66−62.2%31.4% | 64−29.5%24.4% | 106+62.9%33.0% | 190+175%49.1% | 175—38.6% | 91—18.6% | 65—16.2% | 69—14.7% | |
| Short-term investments | 95—54.0% | 95−6.2%54.0% | 110−22.0%56.6% | 129−9.7%53.3% | 83−34.2%47.9% | 102−52.4%48.5% | 141−50.5%53.8% | 143−29.5%44.4% | 127−52.1%32.7% | 214—47.3% | 285—58.2% | 202—50.2% | 264—56.2% | |
| Receivables | 13—7.3% | 13+227%7.3% | 5.8−27.5%3.0% | 12−7.9%5.2% | 4.0−53.8%2.3% | 3.9−41.1%1.9% | 8.0+15.1%3.0% | 14−56.7%4.2% | 8.6−76.1%2.2% | 6.7—1.5% | 7.0—1.4% | 31—7.8% | 36—7.7% | |
| Other current assets | 4.5—2.6% | 4.5−57.5%2.6% | 5.5−70.2%2.8% | 5.9−76.2%2.5% | 5.5−69.0%3.2% | 11−2.5%5.1% | 19+75.6%7.1% | 25+147%7.7% | 18+80.8%4.6% | 11—2.4% | 11—2.2% | 10—2.5% | 9.8—2.1% | |
| Current assets | 160—90.3% | 160−12.4%90.3% | 176−24.2%90.3% | 221−23.1%91.3% | 151−56.0%86.8% | 182−55.1%86.9% | 232−47.8%88.3% | 287−18.9%89.4% | 343−18.6%88.7% | 406—89.8% | 443—90.7% | 355—87.9% | 422—89.5% | |
| Property, plant and equipment | 7.1—4.0% | 7.1−46.6%4.0% | 8.4−44.2%4.3% | 9.4−44.3%3.9% | 11−41.5%6.1% | 13−29.7%6.4% | 15−22.8%5.7% | 17−18.6%5.2% | 18−17.1%4.7% | 19—4.2% | 19—4.0% | 21—5.1% | 22—4.7% | |
| Right-of-use (leased) assets | 7.2—4.1% | 7.2−46.2%4.1% | 8.5−42.9%4.4% | 9.7−40.4%4.0% | 11−38.3%6.3% | 13−29.9%6.4% | 15−27.0%5.7% | 16−24.6%5.1% | 18−22.5%4.6% | 19—4.2% | 20—4.2% | 22—5.4% | 23—4.8% | |
| Total assets | 177—100% | 177−15.7%100% | 194−25.9%100% | 242−24.7%100% | 174−55.1%100% | 210−53.6%100% | 262−46.4%100% | 321−20.3%100% | 387−17.7%100% | 452—100% | 489—100% | 403—100% | 471—100% | |
| Accounts payable | 2.8—1.6% | 2.8−59.6%1.6% | 3.4−22.1%1.7% | 5.5−32.9%2.3% | 7.6−27.8%4.4% | 7.0+13.2%3.4% | 4.3−29.2%1.6% | 8.2+8.9%2.5% | 10+11.0%2.7% | 6.2—1.4% | 6.1—1.2% | 7.5—1.9% | 9.4—2.0% | |
| Debt due within a year | — | — | — | — | — | — | — | — | — | — | — | — | 4.1—0.9% | |
| Current liabilities | 54—30.7% | 54−24.5%30.7% | 53−28.8%27.2% | 71−46.8%29.3% | 75−43.0%43.2% | 72−45.2%34.3% | 74−42.9%28.3% | 133+67.3%41.4% | 132+40.7%34.1% | 131—29.1% | 130—26.6% | 80—19.7% | 94—19.9% | |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Lease liabilities (non-current) | 2.1—1.2% | 2.1−78.5%1.2% | 4.1−64.3%2.1% | 6.0−55.8%2.5% | 7.9−49.7%4.5% | 9.7−45.1%4.6% | 12−41.1%4.4% | 14−36.3%4.2% | 16−32.3%4.0% | 18—3.9% | 20—4.0% | 21—5.3% | 23—4.9% | |
| Total liabilities | 309—175% | 309+4.1%175% | 298+1.1%153% | 309−11.0%128% | 306−10.6%176% | 297−12.8%142% | 294−12.6%112% | 347+13.7%108% | 343+6.7%88.5% | 341—75.4% | 337—68.9% | 305—75.7% | 321—68.2% | |
| Retained earnings | −1,086—−615% | −1,086—−615% | −1,055—−543% | −1,016—−420% | −978—−563% | −931—−444% | −874—−333% | −863—−268% | −787—−203% | −714—−158% | −666—−136% | −618—−153% | −559—−119% | |
| Shareholders' equity | −133—−75.0% | −133—−75.0% | −103—−53.1% | −67—−27.6% | −132−397%−76.2% | −87−178%−41.6% | −32−121%−12.2% | −26−126%−8.0% | 45−70.2%11.5% | 111—24.6% | 152—31.1% | 98—24.3% | 150—31.8% | |
| Total liabilities and equity | 177—100% | 177−15.7%100% | 194−25.9%100% | 242−24.7%100% | 174−55.1%100% | 210−53.6%100% | 262−46.4%100% | 321−20.3%100% | 387−17.7%100% | 452—100% | 489—100% | 403—100% | 471—100% | |
| Shares outstanding | 17—— | 17−80.5%— | 17−80.4%— | 17−80.4%— | 8.6+3.3%— | 85+3.3%— | 85+3.5%— | 84+35.1%— | 8.3r83−86.4%— | 82—— | 82—— | 62—— | 61—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 5.4−28.5%12.0% | 1.2*−34.5%13.7% | 1.3*−33.6%12.8% | 1.3−32.7%8.8% | 1.6*−13.1%13.9% | 1.9*+5.6%19.6% | 1.9*+6.1%3.0% | 1.9+7.9%10.9% | 1.9*+7.9%12.6% | 1.8*—21.1% | 1.8*—7.0% | 1.8—13.5% | 1.7*—1.5% | |
| Share-based compensation | 7.4−59.6%16.4% | 2.2+38.9%23.7% | 2.0−61.8%20.4% | 1.6−71.8%10.8% | 1.7*−72.0%14.2% | 1.6−76.3%16.0% | 5.3−14.5%8.3% | 5.5−8.7%31.8% | 5.9*−4.9%39.9% | 6.5—76.8% | 6.2—24.0% | 6.1—46.6% | 6.2*—5.5% | |
| Cash from operating activities | −129—−287% | −22*—−247% | −38*—−389% | −42—−291% | −26*—−227% | −38*—−394% | −45*−573%−70.2% | −68—−390% | −72*−610%−484% | −65*—−757% | 9.5*—36.8% | −65—−498% | 14*—12.4% | |
| Cash from investing activities | 7.6−93.3%16.9% | 15*−62.9%163% | 19*+650%197% | −45—−312% | 19*−78.6%161% | 40*−72.9%413% | 2.6*—4.0% | −16−125%−93.4% | 87*—591% | 147*—1729% | −80*—−313% | 64—493% | −24*—−20.7% | |
| Debt repaid | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | 0*—0.0% | −4.1—−31.4% | −3.1*—−2.7% | |
| Shares issued | — | 0*—0.0% | — | — | 0*—0.0% | 0*—0.0% | — | — | 0*—0.0% | 0*—0.0% | — | — | — | |
| Cash from financing activities | 103+122193%228% | 0.1*+30.4%1.5% | −0.4*—−4.2% | 103+156074%710% | −0.1*—−0.5% | 0.1*−90.0%1.1% | −0.1*−100%−0.1% | 0.1—0.4% | −0.0*—−0.2% | 1.0*—11.9% | 96*—375% | −3.4—−26.4% | −3.1*—−2.7% | |
| Change in cash | −19—−42.3% | −7.5*−493%−82.3% | −19*—−197% | 16—107% | −7.8*−150%−66.9% | 1.9*−97.7%19.6% | −42*−265%−66.2% | −84—−483% | 16*—106% | 84*—983% | 26*—99.5% | −4.1—−31.3% | −13*—−11.0% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Sutro Biopharma, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Restructuring 2 · Directors and officers 4 · Material agreement 3 · Agreement ended 1 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Agreement endedResults announced | 8-K | |
| Material agreement | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| RestructuringDirectors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2018 | $85 M | No. 1 | $50 to $250 million | 15 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Sutro Biopharma, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $162 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Sr. ScientistMedical Scientists, Except Epidemiologists | 1 | $162 K |
Where: South San Francisco, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $162 K | 1 |
| FY2025 | 6 | 6 | $189 K | 6 |
| FY2024 | 6 | 6 | $156 K | 6 |
| FY2023 | 7 | 7 | $140 K | 7 |
| FY2022 | 2 | 2 | $171 K | 2 |
| FY2021 | 3 | 3 | $211 K | 3 |
| FY2020 | 2 | 2 | $136 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Sutro Biopharma, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | 65 | · | · | · | · | · | 54 | · | · | · | 119 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| effective | 45 people | LayoffWARN notice | South San Francisco, California | Notice list |
| effective | 8 people | LayoffWARN notice | San Carlos, California | Notice list |
| effective | 1 person | LayoffWARN notice | San Mateo County, California | Notice list |
| 50% of workforce | Restructuring planSEC 8-K | “The Company also plans to reduce its workforce by approximately 50%.” | Filing | |
| effective | 62 people | LayoffWARN notice | San Carlos, California | Notice list |
Source: State WARN notices and SEC 8-K item 2.05
How Sutro Biopharma, Inc. compares in Biotechnology
- Market cap$155 M · higher than 41% of 726
- Revenue$102 M · higher than 69% of 647
- Net margin-186.5% · higher than 29% of 408
- Revenue growth65.2% · higher than 78% of 438
- Price / sales1.5× · lower than 90% of 339
- FCF yield7.2% · higher than 97% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Sutro Biopharma, Inc.🇺🇸 | $155 M | — | -186.5% | +65.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Sutro Biopharma, Inc.? Verify and update this profile — free
Show Sutro Biopharma, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.